BACKGROUND: Gastric variceal bleeding is associated with significant morbidity and mortality and limited endoscopic therapeutic options. AIM: The aim of this study was to evaluate the short- and long-term efficacy and safety of endoscopic therapy with 2-octyl-cyanoacrylate in patients with gastric variceal bleeding. METHODS: A single-center retrospective review of patients receiving endoscopic therapy for gastric variceal hemorrhage. Patient demographics, laboratory, and procedural data were collected. Patients were followed to death, liver transplantation, or last follow-up. Success rates were defined as immediate control of bleeding; early re-bleeding (1-7 days), short-term re-bleeding (1-12 weeks), overall survival, and serious procedure complications. RESULTS: A total of 41 patients (39 with cirrhosis) underwent 54 cyanoacrylate injections during study period. Mean age was 57 and 73 % were males. Twenty-four (58.5 %) patients had failed or were deemed ineligible for transjugular intra-hepatic portosystemic shunt, and 5 % were done for primary prophylaxis. Immediate hemostasis was achieved in five active bleeders. During a median survival time of 117 days, early re-bleeding was seen in 1 (2.4 %), short-term re-bleeding in five patients (12 %), and varices were eradicated in 15 (46.8 %) patients on follow-up. Mean MELD score at the time of the first injection was 17.1 ± 7.8. Mean volume injected was 3.4 cc and median number of varices injected per session was one. Eight patients died during the long-term follow-up: metastatic cancer (2), infections (3), liver failure (1), and re-bleeding (2). There were no serious procedure-related complications. CONCLUSIONS: Endoscopic cyanoacrylate therapy appears effective and safe for treatment of patients with bleeding from gastric varices or high-risk stigmata.
BACKGROUND:Gastric variceal bleeding is associated with significant morbidity and mortality and limited endoscopic therapeutic options. AIM: The aim of this study was to evaluate the short- and long-term efficacy and safety of endoscopic therapy with 2-octyl-cyanoacrylate in patients with gastric variceal bleeding. METHODS: A single-center retrospective review of patients receiving endoscopic therapy for gastric variceal hemorrhage. Patient demographics, laboratory, and procedural data were collected. Patients were followed to death, liver transplantation, or last follow-up. Success rates were defined as immediate control of bleeding; early re-bleeding (1-7 days), short-term re-bleeding (1-12 weeks), overall survival, and serious procedure complications. RESULTS: A total of 41 patients (39 with cirrhosis) underwent 54 cyanoacrylate injections during study period. Mean age was 57 and 73 % were males. Twenty-four (58.5 %) patients had failed or were deemed ineligible for transjugular intra-hepatic portosystemic shunt, and 5 % were done for primary prophylaxis. Immediate hemostasis was achieved in five active bleeders. During a median survival time of 117 days, early re-bleeding was seen in 1 (2.4 %), short-term re-bleeding in five patients (12 %), and varices were eradicated in 15 (46.8 %) patients on follow-up. Mean MELD score at the time of the first injection was 17.1 ± 7.8. Mean volume injected was 3.4 cc and median number of varices injected per session was one. Eight patients died during the long-term follow-up: metastatic cancer (2), infections (3), liver failure (1), and re-bleeding (2). There were no serious procedure-related complications. CONCLUSIONS: Endoscopic cyanoacrylate therapy appears effective and safe for treatment of patients with bleeding from gastric varices or high-risk stigmata.
Authors: K Barange; J M Péron; K Imani; P Otal; J L Payen; H Rousseau; J P Pascal; F Joffre; J P Vinel Journal: Hepatology Date: 1999-11 Impact factor: 17.425
Authors: T Kim; H Shijo; H Kokawa; H Tokumitsu; K Kubara; K Ota; N Akiyoshi; T Iida; M Yokoyama; M Okumura Journal: Hepatology Date: 1997-02 Impact factor: 17.425
Authors: Roberto de Franchis; Glenn M Eisen; Loren Laine; Inaki Fernandez-Urien; Juan Manuel Herrerias; Russell D Brown; Laurel Fisher; Hugo E Vargas; John Vargo; Julie Thompson; Rami Eliakim Journal: Hepatology Date: 2008-05 Impact factor: 17.425
Authors: Tom D Catron; George B Smallfield; Le Kang; Richard K Sterling; Mohammad S Siddiqui Journal: Dig Dis Sci Date: 2017-07-12 Impact factor: 3.199
Authors: Benjamin L Bick; Mohammad Al-Haddad; Suthat Liangpunsakul; Marwan S Ghabril; John M DeWitt Journal: Surg Endosc Date: 2018-09-26 Impact factor: 4.584
Authors: Dhiraj Tripathi; Adrian J Stanley; Peter C Hayes; David Patch; Charles Millson; Homoyon Mehrzad; Andrew Austin; James W Ferguson; Simon P Olliff; Mark Hudson; John M Christie Journal: Gut Date: 2015-04-17 Impact factor: 23.059
Authors: Su Jin Kim; Cheol Woong Choi; Dae Hwan Kang; Hyung Wook Kim; Su Bum Park; Young Mi Hong; Ki Tae Yoon; Mong Cho; Hyung Seok Nam; Sm Bakhtiar Ui Islam Journal: Clin Mol Hepatol Date: 2016-12-25
Authors: Zi Wen Wang; Jin Chao Liu; Fang Zhao; Wen Guang Zhang; Xu Hua Duan; Peng Fei Chen; Si Fu Yang; Hong Wei Li; Fu Wen Chen; Hong Sheng Shi; Jian Zhuang Ren Journal: Can J Gastroenterol Hepatol Date: 2020-02-11
Authors: Geunwu Gimm; Young Chang; Hyo-Cheol Kim; Aesun Shin; Eun Ju Cho; Jeong-Hoon Lee; Su Jong Yu; Jung-Hwan Yoon; Yoon Jun Kim Journal: Gut Liver Date: 2018-11-15 Impact factor: 4.519